Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL503709 | 0.98 | PTGS1 (0.97) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504307 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504330 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504293 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504315 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL2472356 | 0.97 | PTGS1 (0.93) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| SCHEMBL31074330 | 0.97 | PTGS1 (0.93) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL11306252 | 0.97 | PTGS1 (0.93) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| Methane SCHEMBL11413480 | 0.95 | PTGS1 (0.90) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 | |
| SCHEMBL10536961 | 0.86 | AKR1C3 (0.75) | AKR1C3AKR1C2PTGS1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20200078333-A1 | Healthier Aging in Domesticated Animals | POSTREL RICHARD (US) | 2020-03-12 | — | — | US | claimed |
| US-20200031916-A1 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES | H. LUNDBECK A/S (DK) | 2020-01-30 | — | — | US | claimed |
| US-20190029993-A1 | QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES | REVIGORON LLC | 2019-01-31 | — | — | US | claimed |
| US-20190030044-A1 | HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING | POSTREL RICHARD (US) | 2019-01-31 | — | — | US | claimed |
| EP-3434691-A1 | ANTI-NGF COMPOSITIONS AND USE THEREOF | AlderBio Holdings LLC (US) | 2019-01-30 | — | — | EP | claimed |
| US-20180305305-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2018-10-25 | — | — | US | claimed |
| EP-2646468-B1 | ANTI-NGF COMPOSITIONS AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2018-07-25 | — | — | EP | claimed |
| WO-2018118197-A1 | HEALTHIER AGING IN DOMESTICATED ANIMALS | POSTREL RICHARD (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2017070448-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-04-27 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| US-5700947-A | HAVING REDUCED SIDE EFFECTS | NICOX S.A. (FR) | 1997-12-23 | — | — | US | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1996032377-A1 | LIPOXYGENASE AND CYCLOOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-10-17 | — | — | WO | claimed |
| EP-0722434-A1 | NITRIC ESTERS HAVING ANTI-INFLAMMATORY AND/OR ANALGESIC ACTIVITY AND PROCESS FOR THEIR PREPARATION | NICOX S.A. (FR) | 1996-07-24 | — | — | EP | claimed |
| US-5516789-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-05-14 | — | — | US | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995009831-A1 | NITRIC ESTERS HAVING ANTI-INFLAMMATORY AND/OR ANALGESIC ACTIVITY AND PROCESS FOR THEIR PREPARATION | NICOX S.A. (FR) | 1995-04-13 | — | — | WO | claimed |
| EP-0548145-A1 | TOPICAL TREATMENT AND COMPOSITION | BEECHAM GROUP plc (GB) | 1993-06-30 | — | — | EP | claimed |
| WO-1992004019-A1 | TOPICAL TREATMENT AND COMPOSITION | BEECHAM GROUP PLC (GB) | 1992-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305305-A1 | 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME | AKR1C3, AKR1C2, AKR1A1 | AKR1C3 1/4885AKR1C2 2/4885PTGS1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.